Medical & Pediatric Oncology and Trials

(P 144) A PHASE 1/2 DOSE ESCALATION/EXPANSION STUDY OF ZN-C3 PLUS GEMCITABINE IN RELAPSED/REFRACTORY OSTEOSARCOMA

(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY

(P 147) ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN

(P 149) CHARACTERISTICS OF PATIENTS WITH BONE AND SOFT TISSUE SARCOMAS REFERRED TO A DEDICATED EARLY PHASE CLINICAL TRIAL CLINIC

(P 150) CLINICAL CHARACTERISTICS OF PRIMARY CUTANEOUS AND SUBCUTANEOUS EWING SARCOMA FAMILY OF TUMORS

(P 151) CLINICAL PRESENTATION OF OSTEOSARCOMA PATIENTS WITH ACUTE METHOTREXATE TOXICITY TREATED WITH GLUCARPIDASE

(P 152) FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 153) IFOSFAMIDE/ETOPOSIDE/CARBOPLATIN REGIMEN AS A POST DOXORUBICIN TREATMENT IN METASTATIC OR RECURRENT SOFT TISSUE SARCOMA

(P 154) IRINOTECAN DOSE SCHEDULE FOR THE TREATMENT OF RECURRENT EWING SARCOMA

(P 155) LATE EVENTS OCCURRING AFTER 5 YEARS IN PEDIATRIC RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP

(P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA

(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL

(P 158) NEOADJUVANT COMBINATION OF DOXORUBICIN, CISPLATIN AND METHOTREXATE IN PATIENTS AGED 24-40 YEARS WITH OSTEOSARCOMA UNDER THE COVERAGE OF HEMODIALYSIS. AMAP2021-7-2. ONGOING TRIAL

(P 159) NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS

(P 160) NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM

(P 161) PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).

(P 162) PAZOPANIB IN THE REAL-WORLD SETTING: DATA FROM THE ITALIAN NATIONAL REGISTRY

(P 163) PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MURINE DOUBLE MINUTE 2–TUMOR PROTEIN 53 ANTAGONIST BI 907828 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS

(P 164) PRELIMINARY PHASE 1B RESULTS OF ABSK021 FOR ADVANCED TENOSYNOVIAL GIANT CELL TUMOR: SIGNIFICANT ANTITUMOR ACTIVITY AND FAVOURABLE SAFETY PROFILE

(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY

(P 166) SARCOMA BRAIN METASTASES: EXPERIENCE AT A SINGLE INSTITUTION

(P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY

(P 168) SYSTEMIC INFLAMMATION INDEX (SII) AS INDEPENDENT PREDICTIVE FACTOR IN PATIENTS WITH L-SARCOMA TREATED WITH TRABECTEDIN - ANALYSIS OF REAL-WORLD EVIDENCE FROM A REFERENCE CENTER

(P 169) WHAT IS THE MOSTAPPROPRIATE STUDY ENDPOINT FOR PHASE IICLINICAL TRIALS IN SOFT TISSUE SARCOMA? - CHARACTERISTIC OF THE CURRENT LANDSCAPE OF PHASE II TRIALS